Anti-BCMA, CD3 Agent CC-93269 Shows Promise for Heavily Pretreated Myeloma

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

Source: CancerNetwork - December 7, 2019 Category: Cancer & Oncology Authors: Silas Inman Source Type: news